secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2022-04-04T23:59:59+00:00
Accession:  0001104659-22-041986
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx Q4 net loss $12.1M; CF Foundation awards up to $15.9M; new Alport program
-------------------------------------------------------------------------------

- Net loss $12.1M in Q4 2021 ($0.14/sh); cash $42.3M; expects funding into Q2 2023.
- CF Foundation therapeutic award up to $15.9M for ELX-02 CF program; $7.0M upfront.
- Phase 2 CF expansion (ELX-02+ivacaftor) topline results expected by end of H1 2022.
- New Alport syndrome program for ELX-02; proof-of-concept trial in up to 8 patients expected H2 2022.
- ZKN-013 FAP mouse model: 50% reduction in polyp burden, 40% in polyp count; 50% survival benefit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465922041986/0001104659-22-041986-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465922041986/tm2211418d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-041986

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer